MET Amplification and Response to MET Inhibitors in Stage IV Lung Adenocarcinoma

Publisher： Karger

E-ISSN： 2296-5262|40|4|198-202

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.40, Iss.4, 2017-03, pp. : 198-202

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

HGF-MET in Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer

By  

Current Signal Transduction Therapy, Vol. 6, Iss. 2, 2011-05 ,pp. : 228-233

Bentham Science Publishers

Access to resources Recommend Favorite

High c‐Met expression in stage I–II pancreatic adenocarcinoma: proposal for an immunostaining scoring method and correlation with poor prognosis

By  

HISTOPATHOLOGY, Vol. 67, Iss. 5, 2015-11 ,pp. : 664-676

John Wiley & Sons Inc

Access to resources Recommend Favorite

High c‐Met expression in stage I–II pancreatic adenocarcinoma: proposal for an immunostaining scoring method and correlation with poor prognosis

By  

HISTOPATHOLOGY, Vol. 309-0167, Iss. 5, 2015-11 ,pp. : 664-676

John Wiley & Sons Inc

Access to resources Recommend Favorite

Developing biomarkers to predict benefit from HGF/MET pathway inhibitors

By  

THE JOURNAL OF PATHOLOGY, Vol. 232, Iss. 2, 2014-01 ,pp. : 210-218

John Wiley & Sons Inc

Access to resources Recommend Favorite

BDNF Val66Met polymorphism and lithium response: a meta-analysis

By Ehret Megan J   Baker William   O’Neill Hannah  

Personalized Medicine, Vol. 10, Iss. 8, 2013-11 ,pp. : 777-784

Future Medicine

Access to resources Recommend Favorite